Avadel Pharmaceuticals plc (AVDL) Financial Statements (2026 and earlier)

Company Profile

Business Address 10 EARLSFORT TERRACE
DUBLIN 2, D02 T380
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

9/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments73,777105,11196,499157,22173,19964,158
Cash and cash equivalent51,37131,16773,98150,70871,7229,774
Short-term investments22,40673,94422,518106,5131,47754,384
Receivables34,09712,1036929,09718,9569,868
Inventory, net of allowances, customer advances and progress billings20,29810,380   3,570
Inventory20,29810,380   3,570
Prepaid expense5,1544,3731,5233,1791,0182,116
Other current assets882913228271457107
Other undisclosed current assets  1,3222,5242,722169,8242,561
Total current assets:134,208134,202100,843192,490263,45482,380
Noncurrent Assets
Operating lease, right-of-use asset1,7022,5911,7132,6522,604 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization453585839285359544
Intangible asset, including goodwill, after accumulated amortization16,83616,83616,83616,83616,83619,304
Goodwill16,83616,83616,83616,83616,83618,491
Intangible asset, excluding goodwill, after accumulated amortization      813
Other noncurrent assets11,03710,15211,32233,77724,93939,274
Other undisclosed noncurrent assets  3321,2321,2253,4459,934
Total noncurrent assets:30,02830,49631,94254,77548,18369,056
TOTAL ASSETS:164,236164,698132,785247,265311,637151,436
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities47,97935,66015,22414,8309,43525,910
Accounts payable7,32811,4337,8907,6792,9346,100
Accrued liabilities40,65124,2277,3347,1516,50119,810
Debt   37,668   
Other liabilities2732611,9415,2705,2003,875
Due to related parties✕✕✕   5,554
Other undisclosed current liabilities582934960900474645
Total current liabilities:48,83436,85555,79321,00015,10935,984
Noncurrent Liabilities
Long-term debt and lease obligation   91,614144,104130,050121,686
Long-term debt, excluding current maturities   91,614142,397128,210121,686
Liabilities, other than long-term debt6,3057,3446,5233,9174,21220,646
Due to related parties✕✕✕   11,773
Other liabilities5,1835,6545,7433,9174,2128,873
Operating lease, liability1,1221,6907801,7071,840 
Other undisclosed noncurrent liabilities35,24932,760   2,319
Total noncurrent liabilities:41,55440,10498,137148,021134,262144,651
Total liabilities:90,38876,959153,930169,021149,371180,635
Equity
Equity, attributable to parent73,84887,739(21,145)78,244162,266(29,199)
Preferred stock  52555 
Common stock965898628586583429
Treasury stock, value      (49,998)
Additional paid in capital891,791855,452589,783549,349566,916434,391
Accumulated other comprehensive loss(24,580)(23,167)(26,341)(23,940)(21,051)(22,806)
Accumulated deficit(794,328)(745,496)(585,220)(447,756)(384,187)(391,215)
Total equity:73,84887,739(21,145)78,244162,266(29,199)
TOTAL LIABILITIES AND EQUITY:164,236164,698132,785247,265311,637151,436

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues169,11727,96311611022,33459,215
Sublease income 128123116110336 
Cost of revenue(15,277)(846)(3,345) (6,105)(17,065)
Cost of product and service sold(15,277)(846)  (5,742)(12,125)
Other undisclosed gross profit      
Gross profit:153,84027,117(3,229)11016,22942,150
Operating expenses(196,239)(164,966)(95,216)(85,599)(10,414)(66,262)
Other undisclosed operating loss   (116)(57)  
Operating income (loss):(42,399)(137,849)(98,561)(85,546)5,815(24,112)
Nonoperating income (expense)4,15087(536)2,126(1,267)(1,987)
Investment income, nonoperating4,15087(536)2,126(832)(1,609)
Other nonoperating expense     (435)(378)
Interest and debt expense(10,830)(23,015)(12,342)(9,942)(12,994)(12,483)
Other undisclosed income from continuing operations before equity method investments, income taxes     3,364 
Loss from continuing operations before equity method investments, income taxes:(49,079)(160,777)(111,439)(93,362)(5,082)(38,582)
Other undisclosed income from continuing operations before income taxes    217  
Loss from continuing operations before income taxes:(49,079)(160,777)(111,439)(93,145)(5,082)(38,582)
Income tax expense (benefit)247501(26,025)15,81612,1105,356
Income (loss) from continuing operations:(48,832)(160,276)(137,464)(77,329)7,028(33,226)
Income (loss) before gain (loss) on sale of properties:✕✕✕✕(77,329)7,028(33,226)
Net income (loss) available to common stockholders, diluted:(48,832)(160,276)(137,464)(77,329)7,028(33,226)

Comprehensive Income ($ in thousands)
Annual | Quarterly

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(48,832)(160,276)(137,464)(77,329)7,028(33,226)
Comprehensive income (loss):(48,832)(160,276)(137,464)(77,329)7,028(33,226)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,413)3,174(2,401)(2,889)1,755610
Comprehensive income (loss), net of tax, attributable to parent:(50,245)(157,102)(139,865)(80,218)8,783(32,616)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: